Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof
21.7.2022 18:00:00 EEST | Business Wire | Press release
Innovaderm’s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences’ VTAMA® (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.
Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.
“This is a great milestone for patients – one that we have been working towards for years,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof’s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.”
VTAMA® cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
“VTAMA® cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,” says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. “We appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum – from mild to severe.”
Dr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103629
For information on Innovaderm’s early to late phase study capabilities, visit our website.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information and Patient Information.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Dermavant Sciences
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005175/en/
Contact information
For more information:
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
Anna Tallman
Vice-President, Medical Affairs
Dermavant Sciences
anna.tallman@dermavant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Defines Its Role as the Technology Behind Better Decisions in the AI Era7.4.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced a renewed brand identity that reflects its role in empowering organizations to make better decisions in complex, high-stakes environments. As organizations increasingly rely on optimization to put their AI-driven insights into action, the Gurobi Optimizer is a foundational component of decision intelligence systems, where different approaches to AI—from prediction to optimization—work together to guide business outcomes. “AI has transformed how organizations generate insight, but insight alone does not drive outcomes—decisions do,” said Duke Perrucci, CEO, Gurobi. “We see optimization as the GPS for AI, enabling users to determine the best possible course of action in complex environments. Those decisions are what drive real outcomes, and we’re proud to be the technology behind them.” Across industries such as energy, supply chain management, manufacturing, and finance, organizations trust Gurobi
Poland's Galaxy Systemy Informatyczne Becomes First Private Enterprise to Buy Quantum Computer from IQM7.4.2026 16:00:00 EEST | Press release
IQM Quantum Computers, a global leader in superconducting quantum computing, today announced a commercial milestone to deploy a hybrid integrated quantum computer at GalaxySystemy Informatyczne Sp. z o.o., marking its first deployment in a private enterprise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407351934/en/ IQM Radiance quantum computer Galaxy has been implementing innovations in security, digitisation, and hardware infrastructure while providing IT solutions, supporting HPC infrastructure to shape Poland’s economy based on data and artificial intelligence. The 54-qubit Radiance system will also be the most advanced quantum computer in Poland, and Galaxy, a provider of technological solutions, will become the first private company in the world to own and operate such quantum infrastructure. The system, which will be installed at Galaxy’s headquarters in Zielona Góra in the fourth quarter of 2026, wil
Cessna SkyCourier Strengthens Mission Versatility With New In‑Flight Operable Door Option7.4.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced a new In-Flight Operable Door option for the passenger variant of its twin-engine, large-utility Cessna SkyCourier turboprop, expanding the aircraft’s Special Mission versatility for military, humanitarian and commercial operations. The functionality is expected to be available as a Special Mission factory-installed option in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407228562/en/ Mission flexibility starts at the Cessna SkyCourier door “An In-Flight Operable Door builds on the Cessna SkyCourier’s reputation for reliability and adaptability, reinforcing its role as a purpose-built solution for high-demand missions,” said Bob Gibbs, vice president, Special Missions Sales. “The option opens new opportunities for customers worldwide, including armed forces, smokejumpers, disaster relief groups and commercial skydiving operators.” The Cessna
Peruvian Army Selects Beechcraft King Air 360C for Multi-Mission Operation7.4.2026 16:00:00 EEST | Press release
The Peruvian Army has signed an agreement to purchase a cargo door equipped Beechcraft King 360C aircraft, which is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, to deliver critical services for communities across the country. With its generous payload, the twin-engine turboprop will enhance the Army’s capability to perform medical evacuations, transport patients and provide rapid humanitarian aid during disaster relief efforts. The aircraft is expected to enter service in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407176246/en/ Beechcraft King Air 360C supporting the Peruvian Army’s emergency response, medical evacuation and disaster relief missions This order follows the delivery of two multi-mission, air medical equipped Beechcraft King Air 360CHW aircraft to the Peruvian Air Force. The King Air 360CHW is cargo door equipped and fitted for operation at higher operating
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery7.4.2026 16:00:00 EEST | Press release
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities. “Enki 4 is a massive step forward for our platform,” said Ali Saberali, Co-Founder & Head of Platform at Variational AI. “We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partners.” Enki 4 now supports the rapid generation of novel, potent, selective, and synthesizable lead-like structures pre-trained on 760 drug targets, a 28% increase over the previous Enki version’s 592 targets, with more to be released soon. The update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom